Company Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:08:21 2026-03-16 pm EDT			5-day change	1st Jan Change
10.10 ^USD	-1.37%		-4.45%	+50.00%

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM

Business description: Novavax, Inc.

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâ€™s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Number of employees: 749

Sales by Activity: Novavax, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Development of Recombinant Vaccines	1.15B	1.98B	984M	682M	1.12B

See all business segments

Geographical breakdown of sales: Novavax, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Rest of North America	-	-	-	-	576M
United States	-	-	-	-	406M
Rest of The World	-	537M	233M	31.92M	126M
Europe	-	824M	268M	93.27M	15.74M
North America	-	194M	29.96M	65.02M	-

See all geographic segments

Executive Committee: Novavax, Inc.

Manager	Title	Age	Since
John Jacobs CEO	Chief Executive Officer	59	2023-01-22
James Kelly DFI	Director of Finance/CFO	60	2021-08-15
Gale Smith CTO	Chief Tech/Sci/R&D Officer	-	-
Raburn Mallory CTO	Chief Tech/Sci/R&D Officer	-	2021-10-03
Robert Walker CTO	Chief Tech/Sci/R&D Officer	-	2023-03-31

See NOVAVAX, INC. governance

Composition of the Board of Directors: Novavax, Inc.

Director	Title	Age	Since
Richard Douglas BRD	Director/Board Member	73	2010-08-05
Rachel King BRD	Director/Board Member	66	2018-10-31
David Mott BRD	Director/Board Member	60	2020-06-15
Gregg Alton BRD	Director/Board Member	60	2020-10-31
Margaret McGlynn CHM	Chairman	66	2025-03-09
Richard Rodgers BRD	Director/Board Member	59	2022-10-28
John Jacobs BRD	Director/Board Member	59	2023-01-22
John Shiver BRD	Director/Board Member	68	2025-03-09
Charles Newton BRD	Director/Board Member	55	2025-04-24

Composition of the Board of Directors

Shareholders: Novavax, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.52 %	15,470,365	9.52 %	157 M $
Shah Capital Management, Inc. 8.959 %	14,558,780	8.959 %	148 M $
BlackRock Advisors LLC 7.357 %	11,955,098	7.357 %	121 M $
STATE STREET CORPORATION 5.861 %	9,523,646	5.861 %	97 M $
Merrill Lynch International 5.102 %	8,290,665	5.102 %	84 M $

List of NOVAVAX, INC. shareholders

Company details: Novavax, Inc.

Novavax, Inc.

21 Firstfield Road

20878, Gaithersburg

+240 268 2000

http://www.novavax.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NOVAVAX, INC.	-1.37%	-4.45%	+20.29%	+68.84%	1.67B
LONZA GROUP AG	+0.27%	-3.29%	-13.88%	-10.15%	42.78B
BEONE MEDICINES AG	+1.74%	-4.48%	+8.93%	+28.46%	31.5B
CELLTRION, INC.	-2.68%	-5.88%	+11.77%	+44.44%	29.99B
IQVIA HOLDINGS INC.	-0.19%	-8.03%	-11.19%	-16.40%	27.65B
REVOLUTION MEDICINES, INC.	+4.16%	-1.02%	+152.42%	+344.11%	18.8B
ASCENDIS PHARMA A/S	+1.79%	-4.13%	+36.23%	+109.69%	13.87B
MEDPACE HOLDINGS, INC.	+0.94%	-5.30%	+38.87%	+148.65%	12.78B
EUROFINS SCIENTIFIC SE	-0.33%	-3.53%	+22.17%	-0.65%	12.39B
IONIS PHARMACEUTICALS, INC.	+1.88%	-4.07%	+110.76%	+106.54%	11.76B
Average	+0.65%	-3.89%	+37.64%	+82.35%	20.32B
Weighted average by Cap.	+0.61%	-4.55%	+25.63%	+61.97%